主要股东
| 股东名称 | 最终控制人 | 持股数(万股) | 占总股本比(%) | 持股变动(万股) | 股票类型 |
|---|---|---|---|---|---|
| 倪昕 | 倪昕 | 63971.14 | 31.81 | 不变 | 普通股 |
| Pink Crystal China Fund, L.P. | Eric Li | 13591.92 | 6.76 | 不变 | 普通股 |
| HHJH Holdings Limited | Hillhouse Investment Management Ltd. | 12623.91 | 6.28 | 不变 | 普通股 |
| OrbiMed Asia Partners, L.P. | OrbiMed Advisors Limited | 11209.72 | 5.57 | 不变 | 普通股 |
| OrbiMed Asia Partners III, L.P. | OrbiMed Advisors III Limited | 10441.82 | 5.19 | 不变 | 普通股 |
| Talent Creation Holdings Limited | 倪昕 | 861.92 | 0.43 | 不变 | 普通股 |
| Chinapharm Group Company Limited | 倪昕 | 847.06 | 0.42 | 不变 | 普通股 |
| Hillhouse Investment Management Ltd. | Hillhouse Investment Management Ltd. | 175.00 | 0.09 | 不变 | 普通股 |
持股变动
| 日期 | 股东名称 | 持股变动(万股) | 变动后持股(万股) | 变动后占比(%) | 性质 |
|---|---|---|---|---|---|
| 2024-10-04 | Boundless Plain Holdings Limited |
|
15548.55 | 29.90 | 好仓 |
| 2024-10-04 | Skycus China Fund, L.P. |
|
15548.55 | 29.90 | 好仓 |
| 2024-10-04 | 李浩良 |
|
15548.55 | 29.90 | 好仓 |
| 2024-09-13 | HongShan Capital Growth Fund I, L.P. |
|
9222.79 | 17.74 | 好仓 |
| 2024-09-13 | HongShan Capital Growth Fund Management I, L.P. |
|
10574.16 | 20.34 | 好仓 |
| 2024-09-13 | HongShan Capital Growth Fund V, L.P. |
|
4183.61 | 8.05 | 好仓 |
| 2024-09-13 | HongShan Capital I, L.P. |
|
3072.09 | 5.91 | 好仓 |
| 2024-09-13 | HongShan Capital Management I, L.P. |
|
3900.57 | 7.50 | 好仓 |
| 2024-09-13 | HSG Growth V Holdco Q, Ltd. |
|
4183.61 | 8.05 | 好仓 |
| 2024-09-13 | HSG Growth V Management, L.P. |
|
4183.61 | 8.05 | 好仓 |
| 2024-09-13 | HSG Holding Limited |
|
18658.34 | 35.88 | 好仓 |
| 2024-09-13 | SNP China Enterprises Limited |
|
18658.34 | 35.88 | 好仓 |
| 2024-09-13 | 沈南鹏 |
|
18658.34 | 35.88 | 好仓 |
| 2022-01-10 | 周新华 |
|
536.91 | 1.07 | 好仓 |
| 2020-10-27 | The Goldman Sachs Group, Inc. |
|
2540.65 | 5.28 | 好仓 |